Preferred Label : drug resistance, viral;
MeSH definition : The ability of viruses to resist or to become tolerant to chemotherapeutic agents
or antiviral agents. This resistance is acquired through gene mutation.;
MeSH synonym : drug resistances, viral; antiviral drug resistance; antiviral drug resistances;
Origin ID : D024882;
UMLS CUI : C0949670;
Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- Metaterm(s)
- Record concept(s)
- Semantic type(s)
The ability of viruses to resist or to become tolerant to chemotherapeutic agents
or antiviral agents. This resistance is acquired through gene mutation.
https://recalls-rappels.canada.ca/fr/avis-rappel/evusheld-tixagevimab-et-cilgavimab-injectables-risque-echec-prophylaxie-ou-du
2022
false
false
false
Canada
French
English
pharmacovigilance note
canada
drug resistance, viral
cilgavimab and tixagevimab drug combination
drug combinations
tixagevimab
cilgavimab
tixagevimab and cilgavimab
antibodies, monoclonal
antiviral agents
Evusheld
injections, intramuscular
COVID-19
COVID-19
Pre-Exposure Prophylaxis
SARS-CoV-2 variants
---
https://www.cochrane.org/fr/CD006495/tests-de-resistance-aux-antiretroviraux-chez-les-personnes-vivant-avec-le-vih
2019
false
false
false
France
United Kingdom
microbial sensitivity tests
drug resistance, viral
hiv infections
hiv infections
acquired immunodeficiency syndrome
review of literature
french abstract
anti-retroviral agents
---
https://apps.who.int/iris/handle/10665/242272
2014
false
false
false
Switzerland
journal article
influenza a virus, h3n2 subtype
influenza a virus, h1n1 subtype
influenza, human
influenza, human
drug resistance, viral
neuraminidase
influenza vaccines
health planning guidelines
---
https://apps.who.int/iris/handle/10665/242040
2013
false
true
false
Switzerland
influenza, human
influenza, human
influenza a virus, h1n1 subtype
influenza a virus, h3n2 subtype
drug resistance, viral
neuraminidase
epidemiological monitoring
technical report
influenza vaccines
---
https://apps.who.int/iris/handle/10665/242132
2013
false
true
false
Switzerland
influenza, human
influenza, human
influenza a virus, h3n2 subtype
influenza a virus, h1n1 subtype
drug resistance, viral
neuraminidase
epidemiological monitoring
guidelines
influenza vaccines
---
https://apps.who.int/iris/handle/10665/241840
2011
false
true
false
Switzerland
drug resistance, viral
technical report
influenza, human
---
http://publications.msss.gouv.qc.ca/msss/fichiers/2010/10-334-02.pdf
2010
false
Canada
French
hepatitis B
comorbidity
hepatitis B vaccines
hiv infections
acquired immunodeficiency syndrome
hepatitis B
drug resistance, viral
antiviral agents
practice guideline
---
https://solidarites-sante.gouv.fr/ministere/documentation-et-publications-officielles/rapports/sante/article/rapport-2010-sur-la-prise-en-charge-medicale-des-personnes-infectees-par-le-vih
2010
true
France
French
patient care management
hiv infections
pregnancy
mass screening
infant, newborn
hiv infections
hiv infections
reproduction
anti-retroviral agents
continuity of patient care
hiv infections
infant
child
adolescent
anti-retroviral agents
drug resistance, viral
hepatitis, viral, human
aids-related opportunistic infections
neoplasms
korean war
technical report
consensus
---
https://apps.who.int/iris/handle/10665/241513
2010
false
Switzerland
French
influenza, human
influenza a virus, h1n1 subtype
oseltamivir
drug resistance, viral
journal article
---
http://www.has-sante.fr/portail/jcms/c_945986/test-genotypique-de-resistance-aux-inhibiteurs-de-lintegrase-document-d-avis
http://www.has-sante.fr/portail/jcms/c_945984/test-genotypique-de-resistance-aux-inhibiteurs-de-l-integrase-document-d-avis
http://www.has-sante.fr/portail/jcms/c_945983/test-genotypique-de-resistance-aux-inhibiteurs-de-l-integrase-rapport-d-evaluation
2010
France
French
HIV integrase inhibitors
genotype
drug resistance, viral
assessment of professional actions
health technology assessment
---
https://apps.who.int/iris/handle/10665/241448
2009
false
Switzerland
French
oseltamivir
influenza, human
influenza a virus, h1n1 subtype
drug resistance, viral
public health guidelines
---
https://www.revmed.ch/RMS/2009/RMS-187/Prevention-et-prise-en-charge-de-la-resistance-antivirale-dans-l-hepatite-B-chronique
2009
Switzerland
French
antiviral agents
reverse transcriptase inhibitors
hepatitis B, chronic
drug resistance, viral
journal article
---
https://medias.vie-publique.fr/data_storage_s3/rapport/pdf/064000613.pdf
2006
France
French
medication adherence
hiv infections
acquired immunodeficiency syndrome
hiv infections
acquired immunodeficiency syndrome
france
prevalence
hiv infections
acquired immunodeficiency syndrome
hiv infections
acquired immunodeficiency syndrome
anti-hiv agents
adult
continuity of patient care
pregnancy
reproductive techniques, assisted
child
adolescent
aids-related opportunistic infections
hepatitis B
hepatitis C
drug resistance, viral
anti-hiv agents
anti-hiv agents
immunotherapy
hiv infections
acquired immunodeficiency syndrome
blood-borne pathogens
mass screening
population surveillance
treatment failure
vaccination
vaccines
sexually transmitted diseases
sexuality
infant, newborn
infant
hiv infections
acquired immunodeficiency syndrome
HIV seropositivity
risk factors
infectious disease transmission, vertical
occupational exposure
chemoprevention
patient care management
patient education as topic
community networks
coinfection
practice guideline
graph
table
---
https://medias.vie-publique.fr/data_storage_s3/rapport/pdf/044000467.pdf
2004
France
French
Therapy cessation
skin biopsy
acquired immunodeficiency syndrome
hiv infections
france
acquired immunodeficiency syndrome
hiv infections
population surveillance
mass screening
hiv infections
acquired immunodeficiency syndrome
hiv infections
acquired immunodeficiency syndrome
anti-hiv agents
anti-hiv agents
patient selection
antiretroviral therapy, highly active
antiretroviral therapy, highly active
risk factors
patient education as topic
anti-hiv agents
continuity of patient care
treatment outcome
medical history taking
physical examination
hiv infections
acquired immunodeficiency syndrome
hiv infections
acquired immunodeficiency syndrome
communication
treatment failure
hiv infections
acquired immunodeficiency syndrome
drug resistance, viral
microbial sensitivity tests
predictive value of tests
microbial sensitivity tests
microbial sensitivity tests
anti-hiv agents
dose-response relationship, drug
anti-hiv agents
drug interactions
anti-hiv agents
quality control
hiv-associated lipodystrophy syndrome
hiv-associated lipodystrophy syndrome
hiv-associated lipodystrophy syndrome
hiv-associated lipodystrophy syndrome
Plastic Surgery Procedures
glucose intolerance
hyperinsulinism
diabetes mellitus
glucose intolerance
diabetes mellitus
hyperinsulinism
glucose intolerance
diabetes mellitus
hyperinsulinism
glucose intolerance
hyperinsulinism
diabetes mellitus
hypertriglyceridemia
hypercholesterolemia
hypertriglyceridemia
hypercholesterolemia
hypertriglyceridemia
hypercholesterolemia
hypercholesterolemia
hypertriglyceridemia
cardiovascular diseases
bone diseases
osteoporosis
bone diseases
osteoporosis
osteonecrosis
acidosis, lactic
mitochondrial diseases
immunotherapy
Interleukin-2
Interleukin-2
aids-related opportunistic infections
hepatitis C
hepatitis C
hepatitis C
ribavirin
ribavirin
interferons
interferons
hepatitis B
hepatitis B
hepatitis B
hepatitis A
hepatitis, chronic
liver cirrhosis
aids-related opportunistic infections
biopsy, needle
cause of death
pneumonia, pneumocystis
toxoplasmosis, cerebral
chemoprevention
tuberculosis
cryptococcosis
cytomegalovirus infections
antibiotic prophylaxis
candidiasis
leishmaniasis, visceral
intestinal diseases, parasitic
hiv infections
acquired immunodeficiency syndrome
mycobacterium infections
herpesvirus 8, human
herpes simplex
health services accessibility
transients and migrants
patient rights
poverty
socioeconomic factors
housing
insurance
prisons
prisoners
hospitalization
patient care
Long-Term care
herpesviridae infections
uterine cervical neoplasms
anus neoplasms
hodgkin disease
vaccination
vaccination
pneumococcal vaccines
meningococcal vaccines
haemophilus vaccines
hepatitis B vaccines
hepatitis A vaccines
BCG vaccine
yellow fever vaccine
signs and symptoms
HIV-2
pregnancy
risk assessment
prenatal diagnosis
infectious disease transmission, vertical
child
pregnancy complications
adolescent
infant, newborn
infant, newborn, diseases
hiv infections
acquired immunodeficiency syndrome
women
reproductive techniques, assisted
contraception
sexuality
sexual behavior
sexually transmitted diseases
sexual dysfunction, physiological
martinique
guadeloupe
french guiana
pregnancy, multiple
Contraindications, Procedure
Contraindications, Drug
HIV seropositivity
lymphoma, Non-Hodgkin
medication adherence
coinfection
practice guideline
---
